Skip to main content

An update on an incident involving one of our systems

Hide
Quest Diagnostics

Carfentanil and Other Fentanyl Analog Prevalence in Clinical Urine Specimens Analyzed Using a High-Throughput Novel Psychoactive Substances Testing Panel

SOFT 2024

Society of Forensic Toxicologists

St Louis, MO, Oct 27-31, 2024

Poster presentation: Carfentanil and Other Fentanyl Analog Prevalence in Clinical Urine Specimens Analyzed Using a High-Throughput Novel Psychoactive Substances Testing Panel

Authors: Meli TM,  Neifeld JR, Smith MP,  Bartock SH

Specialty: Prescription Drug Monitoring, Toxicology

Related content

Test FAQ
Novel Psychoactive Substances (NPS) Panel
Conference Presentation
Novel Psychoactive Substances Most Commonly Identified in Clinical Specimens from November 2023 to April 2024
Conference Presentation
What’s Next on the Drug Abuse Landscape: Development of Laboratory Testing for Novel Psychoactive Substances (NPS)
Conference Presentation
Prevalence of Novel Psychoactive Substances in Routine Prescription Drug Monitoring Clinical Urine Specimens
Audio Podcast
Drug Testing for Stimulants

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only. May include AI-generated and/or AI-modified imagery.